RT Journal Article
SR Electronic
T1 Effectiveness of COVID-19 Vaccines: Eight Months Post Single Dose Vaccination
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.18.21263262
DO 10.1101/2021.09.18.21263262
A1 Naif Khalaf Alharbi
A1 Jaffar A. Al-Tawfiq
A1 Suliman Alghnam
A1 Amal Alwehaibe
A1 Abrar Alasmari
A1 Suliman A. Alsagaby
A1 Faizah Alotaibi
A1 Faisal Alsubaie
A1 Majid Alshomrani
A1 Fayssal M. Farahat
A1 Mohammad Bosaeed
A1 Ahmad Alharbi
A1 Omar Aldibasi
A1 Abdullah M. Assiri
YR 2021
UL http://medrxiv.org/content/early/2021/09/22/2021.09.18.21263262.abstract
AB Objectives To describe the real-world data on the effectiveness of Pfizer-BioNtech BNT162b2 and AstraZeneca-Oxford AZD1222 vaccines against COVID-19 in a large cohort in the Kingdom of Saudi Arabia (KSA).Methods A total of 18,543 subjects received a single-dose of either of the vaccines at one vaccination centre in KSA, and were followed up for three to eight months. Clinical data from medical records, adverse events (AEs) from a self-reporting system, and COVID-19 infection data from the national databases were retrieved and analysed.Results Subjects median age was 33 years old with an average of 27.3 body mass index and the majority were male (60.1%). 92.17% of the subjects had no COVID-19 infection post-vaccination. Diabetes mellitus (p=0.0325), organ transplantation (p=0.0254), and morbid obesity (p=0.0014) were risk factors for infection post-vaccination. Unlike vaccine type, being Saudi, male, or obese was more likely to get the infection earlier. AE reports from 1084 subjects included injection site pain, fatigue, fever, myalgia, headache.Conclusion Single-dose COVID-19 vaccines in KSA showed an effectiveness rate of 92.17% up to eight months follow-up. The rate for AZD1222 was higher than what have been previously reported. Side effects and AEs were within what has been reported in clinical trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by KAIMRC under the grant RC20/180; PI: Naif K. Alharbi.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the IRB at KAIMRC for projects RC20/180 and NRC21R-120-03.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnalysed data are presented in this article, but raw data are available upon request.